QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer
Objective: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Galenos Publishing House
2018-10-01
|
| Colección: | European Journal of Breast Health |
| Materias: | |
| Acceso en línea: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023
|
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|